3rd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Period 3rd Quarter 2012 Filed Oct 19, 2012 Signed by Samantha Ventimiglia, Senior Director, Government Affairs and Public Policy

Official filing
Firm
VERTEX PHARMACEUTICALS INCORPORATED
Client
VERTEX PHARMACEUTICALS INCORPORATED
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions.

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
RICHARD WAYNE OLSON —
SAMANTHA VENTIMIGLIA —

Contacted: Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1809 (112th), H.R. 3381 (112th)

Budget/Appropriations BUD

FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013 (S.3295), provisions related to viral hepatitis funding.

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
RICHARD WAYNE OLSON —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Bills named: S. 3295 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.